for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

22UAy.F

Latest Trade

43.90EUR

Change

-0.40(-0.90%)

Volume

12,998

Today's Range

43.05

 - 

45.07

52 Week Range

11.50

 - 

102.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
44.30
Open
44.00
Volume
12,998
3M AVG Volume
26.98
Today's High
45.07
Today's Low
43.05
52 Week High
102.00
52 Week Low
11.50
Shares Out (MIL)
226.26
Market Cap (MIL)
10,767.82
Forward P/E
-54.50
Dividend (Yield %)
--

Next Event

BioNTech SE at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

Biontech And Pfizer Announce Completion Of Dosing For First Cohort Of Phase 1/2 Trial Of Covid-19 Vaccine Candidates In Germany

Biontech, Pfizer Announce Regulatory Approval From German Authority To Commence First Clinical Trial Of Covid-19 Vaccine Candidates

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioNTech SE - ADR

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

An der Goldgrube 12

55131

Germany

+49.6131.90840

https://biontech.de/

Key Stats

2.44 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2019

0.1K

2020(E)

0.1K
EPS (EUR)

2019

-0.850

2020(E)

-0.859
Price To Earnings (TTM)
--
Price To Sales (TTM)
71.90
Price To Book (MRQ)
25.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
21.25
LT Debt To Equity (MRQ)
15.95
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

GSK aims for one billion doses of booster as COVID-19 vaccine race heats up

GSK <GSK.L>, the world's largest vaccine maker, laid out plans on Thursday to produce 1 billion doses of vaccine efficacy boosters for COVID-19 shots next year, as the race to develop a successful solution to the coronavirus crisis heats up.

VIRUS-TICKER-Reuters-Zählung - Weltweit über 5,5 Millionen Menschen infiziert

Das neuartige Coronavirus breitet sich weiter aus. Es folgen aktuelle Entwicklungen:

VIRUS-TICKER-WHO nennt Nord- und Südamerika neues Epizentrum der Pandemie

Das neuartige Coronavirus breitet sich weiter aus. Es folgen aktuelle Entwicklungen:

FACTBOX-Global pharma industry steps up efforts to battle coronavirus

Drugmakers are rushing to develop a treatment or vaccine for the fast-spreading new coronavirus that has killed over 345,433 people and ravaged financial markets. Gilead Sciences Inc's antiviral remdesivir could be at the forefront of the fight against the virus, after getting...

Thailand says it expects coronavirus vaccine next year after tests in mice

Thailand expects to have a vaccine for the novel coronavirus ready next year, a senior official said on Wednesday, after finding positive trial results in mice.

AstraZeneca in talks with other governments to replicate UK vaccine deal

AstraZeneca Plc said it was in talks with governments around the world to strike coronovirus vaccine production deals similar to one it agreed with Britain over the weekend.

Keenly-watched COVID-19 vaccine 'won't be expensive', developer says

A keenly-watched COVID-19 vaccine will be priced to allow as wide as possible access to it, if it proves successful, and will be made at huge scale to keep costs down and supply up, said the Oxford University professor co-leading its development.

Oxford coronavirus vaccine found protective in small monkey study

A closely watched coronavirus vaccine being developed by scientists at Oxford University appears protective in a small study of six monkeys, promising findings that led to the start of human trials late last month, U.S. and British researchers reported on Thursday.

CureVac's coronavirus vaccine candidate triggered immune response in animal tests

Germany's unlisted CureVac said its experimental coronavirus vaccine was shown to trigger an immune response in animals when given a low dose and the biotech firm was looking at carrying out its first human trials in June.

Moderna's potential coronavirus vaccine gains FDA's 'fast track' status

Moderna Inc said on Tuesday the U.S. Food and Drug Administration granted "fast track" designation to its experimental coronavirus vaccine, a move that speeds up the regulatory review process.

Pfizer, BioNTech set to begin U.S. coronavirus vaccine trial

Pfizer Inc <PFE.N> and BioNTech SE <22UAy.F> said on Tuesday they have begun delivering doses of their experimental coronavirus vaccines for initial human testing in the United States.

Moderna expects mid-stage trials for COVID-19 vaccine to begin shortly

Moderna Inc said on Thursday it expects mid-stage trials for its COVID-19 vaccine to begin shortly while late-stage trials are expected to begin early summer, as the drug developer accelerates its efforts to combat the pandemic.

UPDATE 2-Moderna sees late-stage COVID-19 vaccine trial by summer, shares rise

Moderna Inc sped up plans for its experimental COVID-19 vaccine on Thursday and said it expected to start a late-stage trial in early summer, pushing ahead in the race for developing a safe and effective vaccine.

Exclusive: Sanofi to enroll thousands for its coronavirus vaccine trials

French drugmaker Sanofi SA <SASY.PA> said it plans to enroll thousands of subjects globally for trials of an experimental vaccine for the coronavirus it is developing with GlaxoSmithKline Plc <GSK.L>, and that it has started to discuss advanced purchases with several countries...

Sanofi kündigt klinische Studien für zwei Coronavirus-Impfstoffe an

Der französische Arzneimittelhersteller Sanofi will mit dem Start einer klinischen Studie die Wirksamkeit von zwei experimentellen Impfstoffen gegen das neuartige Coronavirus SARS-CoV-2 überprüfen. Während Phase-I-Impfstoffstudien in der Regel eine kleine Anzahl gesunder...

Pfizer aims for 10-20 million doses of coronavirus vaccine by end-2020

Pfizer aims to make 10-20 million doses of a coronavirus vaccine it is developing with Germany's BioNtech by the end of 2020 for emergency use should it pass tests, the U.S. drugmaker's head of vaccines said on Thursday.

Pfizer aims for 10-20 mln doses of coronavirus vaccine by end-2020 depending on trials

Pfizer aims to make 10-20 million doses of a coronavirus vaccine it is developing with Germany's BioNtech by the end of 2020 for possible emergency use depending on trial results, the U.S. drugmaker's vaccines head said on Thursday.

BRIEF-Biontech And Pfizer Announce Completion Of Dosing For First Cohort Of Phase 1/2 Trial Of Covid-19 Vaccine Candidates In Germany

* ANNOUNCE COMPLETION OF DOSING FOR FIRST COHORT OF PHASE 1/2 TRIAL OF COVID-19 VACCINE CANDIDATES IN GERMANY

Pfizer plans expanded coronavirus vaccine trials, sees 'negligible' hit from outbreak

Pfizer Inc on Tuesday said it expects its experimental coronavirus vaccine to move into expanded clinical trials by October that could allow for emergency use or accelerated approval, as it ramps up efforts to combat the pandemic.

Countries, companies risk billions in race for coronavirus vaccine

By Julie Steenhuysen, Peter Eisler, Allison Martell and Stephanie Nebehay

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up